NV
Novavax
NVAX · NASDAQ
$10.22 -2.94% (-$0.31)
1M +28.55%
Market Cap $1.70B
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$12.15
18.9% upside
Trenutna cena
$10.22
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica NVAX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
1/9Valuation
44 /100
Fair P/S 4.11x
P/E N/A
EV/FFO N/A
Growth
0 /100
Declining Rev. growth 11.10%
EPS growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Gross margin 77.85%
FCF margin 10.53%
Net margin 59.87%
Quality
8 /100
Poor ROIC 36.49%
Asset turnover 0.43x
ROA 25.92%
Debt
43 /100
Moderate Current ratio 2.33x
Int. coverage -18.47x
Debt/Equity N/A
Stability
3 /100
Unstable Beta 2.42x
Profitable years 1
Rev. volatility 66.28%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o NVAX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Charles Jacobs
Employees
749
Headquarters
Gaithersburg
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report